<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on Phase III products like HS-20093, and innovative approaches like TGF-β1 inhibitors and CAR-T therapies, indicating significant R&D prospects and unmet needs in this space.Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/report/global-osteosarcoma-drug-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jvtrf3&amp;utm_campaign=2292816+-+Osteosarcoma+Therapeutics+Pipeline+2026%3a+Explore+25%2b+Companies+and+32%2b+Pipeline+Drugs&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Osteosarcoma - Pipeline Insight, 2026">"Osteosarcoma - Pipeline Insight, 2026"</a> has been added to ResearchAndMarkets.com's offering. The "Osteosarcoma - Pipeline Insight, 2026" report provides in-depth insights into more than 25 companies and 32 pipeline drugs related to osteosarcoma. This comprehensive overview includes analysis of clinical and nonclinical stages, therapeutics assessment by product type, stage, administration route, and molecule type. Inactive pipeline products in this domain are also reviewed. Global Coverage <ul><li>Global Overview</li></ul> Osteosarcoma, a primary malignant bone tumor, accounts for around 20% of similar cases. Subtypes vary in distribution and behavior, with high-grade conventional intramedullary osteosarcoma being the most frequent. Symptoms often begin in the bone, leading to pain and swelling, and mostly occur in the extremities. Commonly affecting the metaphysis of long bones during growth spurts, osteosarcomas more frequently occur during puberty. Etiology involves a combination of genetic and environmental factors, including mutations in RB1 and TP53 genes, and preexisting conditions such as Paget disease or past radiation exposure. Diagnosis requires integrating laboratory tests, imaging, and histopathology. Elevated serum markers and distinct radiographic patterns aid in detection. Treatment involves chemotherapy, surgery, and potentially radiotherapy for metastatic cases, alongside supportive care to manage treatment effects. The report outlines a detailed analysis of the osteosarcoma pipeline, including drug development activities, clinical trials, and product descriptions. Collaboration, licensing, and acquisition details alongside drug profiles and emerging therapies are covered. Report Highlights Academic and industry players are focusing on novel approaches in osteosarcoma R&amp;D. Key emerging drugs include: Osteosarcoma Emerging Drugs <ul><li>HS-20093: This B7-H3-targeted ADC by Hansoh Pharmaceutical, licensed to GSK, is in Phase III development, targeting the B7-H3 protein on tumor cells.</li><li>Vactosertib: A TGF-?1 kinase inhibitor by MedPacto, in Phase I/II, enhances immune cell activity and suppresses cancer proliferation.</li><li>DIT-309: A CAR-T cell therapy from Tcelltech, currently in Phase I, utilizes 4-1BBL-OX40L technology for improved T cell efficacy.</li></ul> Osteosarcoma: Therapeutic Assessment <ul><li>Major Players: Over 25 key companies are involved in drug development, with some in advanced clinical stages, including Hansoh BioMedical R&amp;D Company.</li><li>Phases: Covers over 32 products across various clinical stages.</li><li>Route of Administration: Oral, intravenous, subcutaneous, parenteral, and topical categories are included.</li><li>Molecule Type: Includes recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.</li></ul> The report also examines drug development activities like collaborations, mergers, acquisitions, and provides a detailed assessment of emerging osteosarcoma therapeutics. Osteosarcoma Report Insights <ul><li>Pipeline Analysis</li><li>Therapeutic Assessment</li><li>Unmet Needs</li><li>Impact of Drugs</li></ul> Key Players <ul><li>Hansoh BioMedical R&amp;D Company</li><li>MedPacto, Inc.</li><li>Tcelltech Inc.</li><li>Zentalis Pharmaceuticals</li><li>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</li></ul> Key Products <ul><li>HS-20093</li><li>Vactosertib</li><li>DIT-309</li><li>Azenosertib</li><li>IM83</li></ul> Key Topics Covered: Introduction Executive Summary Osteosarcoma: Overview <ul><li>Introduction</li><li>Signs and Symptoms</li><li>Causes</li><li>Pathophysiology</li><li>Diagnosis</li><li>Disease Management</li></ul> Pipeline Therapeutics <ul><li>Comparative Analysis</li></ul> Therapeutic Assessment <ul><li>Assessment by Product Type</li><li>Assessment by Stage and Product Type</li><li>Assessment by Route of Administration</li><li>Assessment by Stage and Route of Administration</li><li>Assessment by Molecule Type</li><li>Assessment by Stage and Molecule Type</li></ul> Osteosarcoma- Analytical Perspective Late Stage Products (Phase III) <ul><li>Comparative Analysis</li></ul> HS-20093: Hansoh BioMedical R&amp;D Company <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Mid Stage Products (Phase II) <ul><li>Comparative Analysis</li></ul> Drug name: Company name <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Early Stage Products (Phase I) <ul><li>Comparative Analysis</li></ul> DIT-309: Tcelltech Inc. <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Preclinical and Discovery Stage Products <ul><li>Comparative Analysis</li></ul> Drug name: Company name <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Inactive Products <ul><li>Comparative Analysis</li></ul> Osteosarcoma Key Companies Osteosarcoma Key Products Osteosarcoma- Unmet Needs Osteosarcoma- Market Drivers and Barriers Osteosarcoma- Future Perspectives and Conclusion Osteosarcoma Analyst Views Osteosarcoma Key Companies Appendix List of Tables Table 1 Total Products for Osteosarcoma Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical &amp; Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products List of Figures Figure 1 Total Products for Osteosarcoma Figure 2 Late Stage Products Figure 3 Mid Stage Products Figure 4 Early Stage Products Figure 5 Preclinical and Discovery Stage Products Figure 6 Assessment by Product Type Figure 7 Assessment by Stage and Product Type Figure 8 Assessment by Route of Administration Figure 9 Assessment by Stage and Route of Administration Figure 10 Assessment by Molecule Type Figure 11 Assessment by Stage and Molecule Type Figure 12 Inactive Products A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Hansoh BioMedical R&amp;D Company</li><li>MedPacto, Inc.</li><li>Tcelltech Inc.</li><li>Zentalis Pharmaceuticals</li><li>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</li><li>Cellectar Biosciences, Inc.</li><li>Valo Therapeutics Oy</li><li>BioEclipse Therapeutics</li><li>Emerald Clinical Inc.</li><li>USWM CT, LLC</li></ul> For more information about this clinical trials report visit <a href="https://www.researchandmarkets.com/report/global-osteosarcoma-drug-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jvtrf3&amp;utm_campaign=2292816+-+Osteosarcoma+Therapeutics+Pipeline+2026%3a+Explore+25%2b+Companies+and+32%2b+Pipeline+Drugs&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/5veug3</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzkyYzQwOTUtMTk1Yy00MzZlLTgzZTUtZDkyZTFjOGUxMmUyLTEwMjY3MzctMjAyNi0wNy0wMy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Osteosarcoma Therapeutics Pipeline 2026: Explore 25+ Companies and 32+ Pipeline Drugs

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn